Acurx Pharmaceuticals Q2 2024 Earnings Report $0.43 +0.01 (+1.53%) As of 09:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Acurx Pharmaceuticals EPS ResultsActual EPS-$0.26Consensus EPS -$0.28Beat/MissBeat by +$0.02One Year Ago EPS-$0.28Acurx Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAcurx Pharmaceuticals Announcement DetailsQuarterQ2 2024Date8/9/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptPress ReleaseACXP Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Remove Ads Acurx Pharmaceuticals Earnings HeadlinesHC Wainwright Brokers Raise Earnings Estimates for ACXPMarch 23 at 1:33 AM | americanbankingnews.comWhat is HC Wainwright's Forecast for ACXP FY2029 Earnings?March 22, 2025 | americanbankingnews.comAI Boom Takes a Shocking Turn…AI is Creating Fortunes… (but not where you think!) Bryce Paul and the team at Crypto101 just released a brand-new report…March 26, 2025 | Crypto 101 Media (Ad)HC Wainwright Reiterates "Buy" Rating for Acurx Pharmaceuticals (NASDAQ:ACXP)March 21, 2025 | americanbankingnews.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | msn.comAcurx reports Q4 EPS (16c) vs. (37c) last yearMarch 18, 2025 | markets.businessinsider.comSee More Acurx Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Acurx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Acurx Pharmaceuticals and other key companies, straight to your email. Email Address About Acurx PharmaceuticalsAcurx Pharmaceuticals (NASDAQ:ACXP), a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.View Acurx Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles After Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of Earnings Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
